Talk:Incyte

[Untitled]
Basic financial information is out of date by several years, and can be verified easily with more current information. I am updating to the 2020 numbers https://www.nasdaq.com/market-activity/stocks/incy/financials DonInUtah (talk) 01:23, 27 July 2021 (UTC)

Updated some of the company information and list of current drugs per verified information and SEC filings. I will look through other sections of the edit request to see that they are independently verified, meet wikipedia guidelines, and will include or exclude accordingly. DonInUtah (talk) 23:56, 26 July 2021 (UTC)

Edit Request
My name is Catalina Loveman and work for Incyte, a biotechnology company. In my role as Executive Director of Public Affairs, I manage all corporate communications efforts for the company. To be transparent, I will list my COIs, brands and any articles I work on below.

Company – Incyte

I am aware of Wikipedia's policies and guidelines, including those on WP:COI, WP:RS, WP:V and WP:NPOV, and I will abide by them. My edit suggestions will be restricted to Talk pages, and I will not engage in directly editing any articles related to the company/brands which I present, aside from correcting/reverting blatant misinformation or obvious vandalism.

On any pages where I may suggest changes, I will be sure to disclose relevant relationships in the interest of transparency on the Talk pages and state that I am not NPOV.

If you have any questions about my editing activities, please leave me a message on my User Talk page.

I would like to propose the following edits to the Incyte infobox:


 * Update financials to be current as of 2020: Net income (decrease) $US 149.85 million (2020); Total assets $US 3.56 billion (2020); Total equity $US 2.61 billion (2020)
 * In “Number of employees,” reflect publicly-available figure: 1,600+

I would like to propose the following edits to the introduction for accuracy:
 * Add a second sentence to reflect number of employees: It employs more than 1,600 employees.
 * Update the following paragraphs in this section to more accurately describe Incyte medicines (i.e., the company has more than one drug): It receives royalties from three products – Jakavi® (ruxolitinib) ex-U.S., which is licensed to Novartis, and Olumiant® (baricitinib) and Tabrecta® (capmatinib) globally, which are licensed to Eli Lilly and Novartis, respectively. The company is advancing a portfolio of medicines across Oncology and Inflammation & AutoImmunity.

Finally, I would like to propose the addition of an external link: Incyte Corporate Website (www.incyte.com).

Please let me know if you have any feedback to these proposed changes.

Details about founding?
There seems to be something odd going on with the dates of founding. "The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware." First off, from the reference it looks like the merger actually officially took effect in 2003, it's just that Incyte lists 2002 as their founding date (https://www.incyte.com/who-we-are/biopharmaceutical-research). And it's also rather suspicious that they happened to have the same name as another company they're merging with.

To me it sure sounds like "Genomics" was a "shell" company specifically set up to take over "Pharmaceuticals" (and probably restructure their corporate structure.) - That is, it isn't really a "merger" of two independent companies, but rather it's a corporate restructuring which was framed as a merger for legalistic purposes. I'm not sure if Wikipedia readers are best served by the current phrasing, though since I'm lacking a bunch of the details and Incyte officially claim 2002 as their founding date I'm not sure how best to rephrase things. -- 129.59.122.107 (talk) 18:36, 13 February 2023 (UTC)